Equine ANP antibody and antigen (recombinant protein)

Diagnostic anti-Equine ANP antibodies pairs and antigen for animal health (animal Equine/Horse hypertension, cardiac hypertrophy and heart failure) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Equine disease testing products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-EQU-ANP-Ag01Equine ANP$3090.00
GMP-EQU-ANP-Ab01Anti-Equine ANP mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-ANP-Ab02Anti-Equine ANP mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-ANP-Ab03Anti-Equine ANP human monoclonal antibody (mAb)$3090.00
GMP-EQU-ANP-Ab04Anti-Equine ANP human monoclonal antibody (mAb)$3090.00

Size： 1mg | 10mg | 100mg



Product Description

Cat No. GMP-EQU-ANP-Ag01
Product NameEquine ANP
Target/BiomarkerEquine ANP
Expression platformE.coli
IsotypesRecombinant Antigen
Bioactivity validationAnti-Equine ANP antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in ANP level test of animal Equine/Horse with hypertension, cardiac hypertrophy and heart failure.
TagHis
Reconized/Reactive SpecicsEquine ANP
Product descriptionRecombinant Equine ANP protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-ANP-Ab01,GMP-EQU-ANP-Ab02
Target/BiomarkerEquine ANP
Product NameAnti-Equine ANP mouse monoclonal antibody (mAb)
Expression platformCHO
Isotypes Mouse IgG
Bioactivity validationRecombinant Equine ANP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine ANP antibodies in Equine ANP level test of animal Equine/Horse with hypertension, cardiac hypertrophy and heart failure.
Product descriptionAnti-Equine ANP mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine ANP antibodies.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-ANP-Ab03,GMP-EQU-ANP-Ab04
Target/BiomarkerEquine ANP
Product NameAnti-Equine ANP human monoclonal antibody (mAb)
Expression platformCHO
IsotypesHuman lgG1
Bioactivity validationRecombinant Equine ANP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine ANP antibodies in Equine ANP level test of animal Equine/Horse with hypertension, cardiac hypertrophy and heart failure.
Product descriptionAnti-Equine ANP mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker Information


     Atrial Natriuretic Peptide (ANP), a biologically active peptide hormone, holds a pivotal role in the equine cardiovascular system. This 28-amino acid molecule is primarily synthesized and secreted by the cardiac atria in response to increased cardiac wall tension, pressure, and stretch. ANP's synthesis is regulated by various factors, including the distension of atrial myocytes, neurohormonal influences, and circulating fluid volume. Once released into the bloodstream, ANP exerts a multifaceted influence on cardiovascular and renal physiology.

    ANP's most prominent action is its vasodilatory effect on blood vessels, particularly on the afferent arterioles within the kidneys. This vasodilation increases renal blood flow and the glomerular filtration rate, ultimately leading to enhanced sodium and water excretion in the urine. By opposing the renin-angiotensin-aldosterone system (RAAS), ANP reduces sodium reabsorption in the distal tubules of the nephron. This dual mechanism of action effectively decreases blood volume and blood pressure, serving as a counterbalance to the vasoconstrictive and sodium-retentive effects of the RAAS.

    Moreover, ANP's impact extends beyond the cardiovascular system. It exerts an inhibitory effect on the hypothalamus and pituitary gland, suppressing the release of antidiuretic hormone (ADH), also known as vasopressin. This further enhances the excretion of water and electrolytes, aiding in the regulation of body fluid balance.

    In summary, ANP acts as a guardian of cardiovascular and renal homeostasis in horses, finely tuning blood pressure, fluid balance, and electrolyte concentrations. Its intricate regulatory mechanisms make it a crucial biomarker in equine medicine and a key player in maintaining overall equine health. 



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.